Ranolazine exerts a positive effect on glucose control and is a well-tolerated agent for patients with diabetes.

Review question / Objective: Objectives of this study: On the one hand, the efficacy and safety of combination chemotherapy with targeted drugs (mainly AIS, PARPIS and ICIS) in recurrent ovarian cancer were reassessed by including the latest and most comprehensive data.On the other hand, evidence-based medicine is used to guide clinical practice to provide the best b e n e fi t p l a n f o r d i ff e r e n t c l i n i c a l INPLASY 1 International Platform of Registered Systematic Review and Meta-analysis Protocols INPLASY PROTOCOL Targeted agents in combination with chemotherapy for recurrent ovarian cancer: an updated systematic review and meta-analysis Zhang, Y 1 ; Fan, HZ 2 . To cite: Zhang et al. Targeted agents in combination with chemotherapy for recurrent ovarian cancer: an updated systematic review and metaanalysis. Inplasy protocol 202140049.